MARKET

OTIC

OTIC

Otonomy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.760
-0.100
-5.38%
After Hours: 1.780 +0.02 +1.14% 18:50 09/24 EDT
OPEN
1.860
PREV CLOSE
1.860
HIGH
1.869
LOW
1.730
VOLUME
172.28K
TURNOVER
--
52 WEEK HIGH
6.98
52 WEEK LOW
1.140
MARKET CAP
99.76M
P/E (TTM)
-2.0750
1D
5D
1M
3M
1Y
5Y
What Is The Ownership Structure Like For Otonomy, Inc. (NASDAQ:OTIC)?
If you want to know who really controls Otonomy, Inc. ( NASDAQ:OTIC ), then you'll have to look at the makeup of its...
Simply Wall St. · 3d ago
Otonomy to Participate in Two Upcoming Investor Conferences
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in two upcoming virtual conferences:
GlobeNewswire · 09/02 11:37
DAFNA Capital Management LLC Buys Theravance Biopharma Inc, Nurix Therapeutics Inc, F-star ...
GuruFocus News · 08/24 16:38
Return on Capital Employed Overview: Otonomy
After pulling data from Benzinga Pro it seems like during Q2, Otonomy (NASDAQ:OTIC) brought in sales totaling $35.00 thousand. However, earnings decreased 2.43%, resulting in a loss of $12.13 million.
Benzinga · 08/20 18:05
BRIEF-Otonomy Appoints Jill Broadfoot To Board Of Directors
reuters.com · 08/19 13:13
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 12:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OTIC. Analyze the recent business situations of Otonomy through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OTIC stock price target is 6.30 with a high estimate of 9.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 74
Institutional Holdings: 37.88M
% Owned: 66.83%
Shares Outstanding: 56.68M
TypeInstitutionsShares
Increased
21
5.31M
New
10
1.63M
Decreased
17
1.02M
Sold Out
13
1.45M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Independent Director
Jay Lichter
President/Chief Executive Officer/Director
David Weber
Chief Financial Officer
Paul Cayer
Chief Technology Officer
Robert Savel
Chief Scientific Officer
Alan Foster
Director
Jill Broadfoot
Independent Director
James Breitmeyer
Independent Director
Vickie Capps
Independent Director
Ciara Kennedy
Independent Director
Iain McGill
Independent Director
Theodore Schroeder
No Data
About OTIC
Otonomy, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in development for the treatment of tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss.

Webull offers kinds of Otonomy Inc stock information, including NASDAQ:OTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OTIC stock methods without spending real money on the virtual paper trading platform.